| Name | Ensitrelvir fumarate |
|---|---|
| Synonyms | S-217622 |
| Description | Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | In a cytopathic effect (cpe)-inhibition assay of SARS-CoV-2 infected VeroE6/TMPRSS2 cells, Ensitrelvir fumarate shows the EC50 values are approximately 0.4 μM for both wild-type virus and Alpha, Beta, Gamma and Delta variants. EC50 values for SARS-CoV and MERS-CoV were 0.21 and 1.4 μM respectively[1]. |
| In Vivo | Ensitrelvir fumarate dose-dependently inhibits intrapulmonary replication of SARS-CoV-2 in mice[2]. |
| References |
| Molecular Formula | C26H21ClF3N9O6 |
|---|---|
| Molecular Weight | 647.95 |